What a skin booster actually is

Start with the word, because it is doing a lot of quiet work. A booster is not a filler. A filler adds structure and volume: it lifts a cheek, sharpens a jaw, plumps a lip. A booster does something less obvious. It is placed into the skin to change the quality of the tissue: hydration, elasticity, smoothness, that hard-to-fake look of skin that holds water well.

Most boosters are built on hyaluronic acid. Hyaluronic acid is the molecule that lets young skin hold onto water, and a 2012 review in Dermato-Endocrinology described it as the key molecule in skin moisture, with a striking capacity to retain water. As skin ages, its hyaluronic acid content and its ability to make collagen both fall. A separate 2006 paper in the American Journal of Pathology documented reduced collagen production in chronically aged skin. Put those two together and you have the plain biology of why skin looks drier, thinner, and less springy over time.

Booster brands answer this in different ways, and the differences matter more than the marketing suggests. A quick, neutral map of the category:

Notice the honest line in that last row. Everything above it happens in a clinic, with a needle held by a trained person, placed into the skin. The last row happens at home and stays much shallower. Same active families, very different depth and control. Holding that distinction in mind is the whole point of this guide.

"The key molecule involved in skin moisture is hyaluronic acid, which has a unique capacity for retaining water." Papakonstantinou, Roth & Karakiulakis, Dermato-Endocrinology, 2012

Why boosters exploded, and why the ingredients moved home

Two things happened at once. First, taste changed. A decade of very visible filler pushed a counter-reaction toward looking rested rather than reworked. Boosters fit that mood: subtle, quality-first, no obvious volume. Second, the science moved. The newest boosters lean on regenerative actives, polynucleotides and PDRN, peptides, and exosomes, rather than hyaluronic acid alone. Industry trackers describe exactly this shift toward collagen-stimulating, repair-signalling injectables, with especially fast adoption in Korea.

Here is the part that matters for anyone reading at home. Those same active families are now in over-the-counter serums. PDRN serums, copper peptide serums, growth factor serums, they are all on the shelf. Which raises the obvious question: if the molecule is in a bottle I can buy, why pay a clinic?

The answer is not marketing. It is skin. And it is worth understanding properly, because it is the one fact that tells you whether any at-home approach is worth your money.

The delivery problem: the fact that decides everything

Your skin's outer layer, the stratum corneum, is a barrier by design. It keeps water in and most things out. That is wonderful for survival and inconvenient for skincare, because many of the most interesting actives are exactly the molecules the barrier blocks best: large, or water-loving, or both.

Copper peptide GHK-Cu is a useful worked example. It has more than fifty years of research behind it. A 2018 review in the International Journal of Molecular Sciences catalogued its ability to increase collagen, elastin, and glycosaminoglycan synthesis and to support the function of dermal fibroblasts, the cells that build the skin's scaffolding. A foundational 1988 paper in FEBS Letters had already shown the copper tripeptide stimulating collagen synthesis in fibroblast cultures. The molecule is not in question. Getting enough of it to the right depth from a cream is.

This is where micro-delivery earns its place, and the evidence is specific rather than hand-waved. A 2015 study in Pharmaceutical Research tested microneedle-mediated delivery of copper peptide through skin and found that almost none of the peptide crossed intact skin, while a measurable amount passed through once microneedles had created the channels. Growth factors tell a similar story. In a controlled split-face study, a micro-spicule preparation carrying epidermal growth factor produced significantly greater gains in dermal density and depth than the same growth factor in a plain cream, with the researchers pointing to skin penetration as the limiting factor for topical delivery. A 2023 systematic review in the Journal of Cosmetic Dermatology concluded that topical growth-factor preparations do appear to help facial skin, though largely on the basis of investigator and participant assessments, while noting that the evidence still leans on uncontrolled studies and needs stronger trials.

That last caveat is not a hedge for legal comfort. It is the truth of the situation, and stating it is how you tell an honest guide from a sales page. Improving delivery is real and worth having. It is not the same as the depth, dose, and precision of a treatment a clinician injects.

Meet the actives, and what each one is really for

The regenerative boosters and the better at-home serums draw from the same short list of ingredients. Knowing what each one does, and where its evidence is strong versus still forming, is the difference between buying on the label and buying on the biology. Here is the honest read on the four that matter most.

Hyaluronic acid: the water molecule

This is the base of most boosters for a reason. Hyaluronic acid is the skin's own humectant, and the 2012 Dermato-Endocrinology review framed it as the key molecule controlling skin moisture, prized for how much water it holds relative to its size. Topically, it plumps the look of skin by drawing in water at the surface. Injected or infused deeper, its role is more structural. It is the least controversial ingredient in the category and the easiest to feel working, because hydration shows up fast. What hydration alone does not do is rebuild the deeper scaffolding, which is where the next three come in.

PDRN and polynucleotides: the repair signal

PDRN, short for polydeoxyribonucleotide, and the broader polynucleotide family are the actives driving the newest generation of boosters. The mechanism is genuinely interesting. A 2017 review in Frontiers in Pharmacology described PDRN as an agonist at the adenosine A2A receptor, a pathway tied to tissue repair, and noted that it also feeds nucleotides into the cell's salvage pathway, the recycling route cells use to rebuild. In plain terms, it is less a passive ingredient and more a signal that nudges repair activity.

Two honest caveats belong here. First, much of the strongest PDRN evidence comes from studies of a registered injectable drug, in clinical or animal settings, rather than over-the-counter serums, and some of that research is authored or funded by parties with a commercial interest in PDRN, so an at-home serum result should be read as appearance-level and not as equivalent to those studies. Second, source matters less than people think. Traditional PDRN is purified from salmon or trout; bioengineered PDRN is made by fermentation. The molecule works through the same biology, but the fermentation route avoids an animal-derived source and can be more consistent. We go deeper on that trade-off in our article on salmon versus bioengineered PDRN.

Copper peptide GHK-Cu: the scaffolding support

If PDRN is the newcomer, GHK-Cu is the veteran, with a research trail going back to the 1970s. The 2018 International Journal of Molecular Sciences review is the one to know: it documents GHK-Cu increasing collagen, elastin, and glycosaminoglycan synthesis and supporting dermal fibroblasts, the cells that build and maintain the skin's structure. The foundational 1988 FEBS Letters paper showed the copper tripeptide stimulating collagen synthesis in fibroblast cultures directly. This is a molecule aimed squarely at the firmness and resilience side of skin quality rather than surface hydration. Its one persistent problem is the one this whole guide keeps returning to: getting enough of it deep enough from a topical. Our dedicated guide to GHK-Cu copper peptides covers the fifty-year trail in full.

Epidermal growth factor: the messenger, with an asterisk

EGF, which appears on ingredient labels as sh-Oligopeptide-1, is a signalling protein involved in how skin cells proliferate and repair. Topical growth-factor serums are popular, and a 2023 systematic review in the Journal of Cosmetic Dermatology found that they do appear to help, though largely on the basis of investigator and participant assessments rather than large controlled trials. The asterisk is delivery, and it is a big one. EGF is a relatively large protein, and in a controlled split-face study a micro-spicule form of EGF produced significantly greater improvement in dermal density and depth than the same EGF in a plain cream, which the researchers attributed to better skin penetration. In other words, EGF is a strong example of an active whose value depends heavily on how it is delivered. Our article on EGF and micro-infusion goes further on this.

Step back and a pattern is obvious. Three of the four most interesting actives, PDRN, GHK-Cu, and EGF, share the same limitation as a topical: they are large or water-loving molecules that the skin barrier holds at the door. That shared limitation is the reason micro-infusion exists as a home format, and the reason the criteria below start with delivery.

How to judge any at-home skin booster

If you are weighing an at-home kit, or deciding between a kit and a clinic, these are the criteria that separate something useful from a gadget. Use them on us too.

Red flags when shopping for an at-home booster

The at-home category attracts marketing that outruns the evidence. A few specific claims should make you slow down and read more carefully, because they usually signal a product hoping you will not ask the delivery question.

None of this means at-home tools do not work. It means the trustworthy ones tend to be specific, honest about depth, and clear about who should skip them. Specificity is the tell.

At-home micro-infusion versus injectable boosters

This is the comparison most people actually want, framed neutrally. It is a comparison of categories, not a claim that one replaces the other.

Read that table as a fork, not a hierarchy. If your goal is the specific, measurable outcome an injectable delivers, the honest recommendation is a qualified clinician. If your goal is an affordable, repeatable, appearance-focused routine you can run for years using hyaluronic acid, PDRN, growth factor, and copper peptide, an at-home micro-infusion kit is a sensible way to do that. Different jobs.

"Is there an at-home Profhilo?" A straight answer

Short version: no, and it is worth being clear about why. Profhilo is a specific injectable product, placed by a clinician, and in the United States it is not currently approved for injection, which is a large reason people search for an alternative in the first place. A U.S. approval process was reported to be underway in 2026, so that status may change. If you want an in-clinic option that is FDA-approved in the U.S. today, SkinVive by Juvederm is the hyaluronic acid skin-quality injectable that holds that clearance. But nothing you buy for home use is Profhilo or an equal to it.

The useful version: if you cannot or would rather not have injectable bioremodelling, the closest home category is a micro-infusion routine that delivers hyaluronic acid and repair-signalling actives past the surface. It works on skin quality in the same broad spirit, hydration and the look of firmness, at a fraction of the cost and with no needle in a clinic. It will not bioremodel your dermis the way an injectable is designed to. Anyone telling you it will is selling, not informing.

The MicroInfuser Kit, scored

A scorecard, judged by the same criteria above. We keep two dimensions deliberately low, depth versus a clinic booster and speed of visible change, because that is the honest picture of what any at-home tool can do.

Editorial log: Published [DATE]. Reviewed by the EvenSkyn Skin Science Desk. Independent medical review by Dr. Lisa Hartford pending; the "medically reviewed" byline must not be shown until that review is complete. All 13 cited sources were verified against their original PubMed or publisher records. Regulatory and market figures were current as of July 2026 and should be re-checked before publication, as Profhilo's U.S. approval status in particular is changing. Product specifications to be reconciled against the current MicroInfuser product page and User Manual before publication. Competitor and cost details to be re-checked against live listings before publication.